Nanobiotix Announces FDA Acceptance of Protocol Amendment for NANORAY-312 Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 04 2026
0mins
Should l Buy NBTX?
Source: Newsfilter
- Protocol Amendment: Nanobiotix announced the FDA's acceptance of a protocol amendment for its NANORAY-312 study, eliminating the planned interim analysis and modifying the final analysis to include fewer events, which could accelerate the global registration pathway for JNJ-1900 in head and neck cancer, thereby providing earlier revenue generation opportunities for the company.
- Revenue Potential: Under the licensing agreement, Nanobiotix anticipates receiving hundreds of millions in aggregate payments over the next few years, contingent upon achieving remaining development and regulatory milestones related to JNJ-1900 in head and neck and lung cancers, significantly enhancing the company's financial position and market competitiveness.
- Innovative Mechanism: JNJ-1900 (NBTXR3) is a novel oncology product designed to induce significant tumor cell death through a one-time intratumoral injection activated by radiotherapy, potentially scalable across various solid tumors, further advancing the company's R&D strategy.
- Strategic Collaboration: Nanobiotix's licensing agreement with Janssen Pharmaceutica for the global co-development and commercialization of JNJ-1900 underscores the company's robust collaborative network in oncology, aiming to enhance market penetration through various therapeutic combinations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NBTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NBTX
Wall Street analysts forecast NBTX stock price to fall
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 48.240
Low
3.50
Averages
3.50
High
3.50
Current: 48.240
Low
3.50
Averages
3.50
High
3.50
About NBTX
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nanobiotix Receives FDA Approval for Study Protocol Amendment
- FDA Approval: Nanobiotix (NBTX) announced that the FDA has accepted a protocol amendment for the NANORAY-312 study evaluating JNJ-1900 in locally advanced head and neck squamous cell cancers, marking a significant advancement in the company's oncology research.
- Study Design Changes: The new protocol amendment submitted by Johnson & Johnson eliminates the interim analysis and modifies the final analysis to include fewer events, which is expected to expedite the research timeline and potentially shorten the path to market.
- Product Background: JNJ-1900 (NBTXR3) is an investigational oncology product made of functionalized hafnium oxide nanoparticles administered via a one-time intratumoral injection and activated by radiotherapy, demonstrating potential across multiple solid tumor indications.
- Stock Price Fluctuation: Despite NBTX's stock trading between $3.26 and $41.89 over the past year, it closed at $31.16 on Monday, down 11.28%, reflecting market caution regarding the study's progress.
See More
Nanobiotix Announces FDA Acceptance of Protocol Amendment for NANORAY-312 Clinical Trial
- Protocol Amendment: Nanobiotix announced the FDA's acceptance of a protocol amendment for its NANORAY-312 study, eliminating the planned interim analysis and modifying the final analysis to include fewer events, which could accelerate the global registration pathway for JNJ-1900 in head and neck cancer, thereby providing earlier revenue generation opportunities for the company.
- Revenue Potential: Under the licensing agreement, Nanobiotix anticipates receiving hundreds of millions in aggregate payments over the next few years, contingent upon achieving remaining development and regulatory milestones related to JNJ-1900 in head and neck and lung cancers, significantly enhancing the company's financial position and market competitiveness.
- Innovative Mechanism: JNJ-1900 (NBTXR3) is a novel oncology product designed to induce significant tumor cell death through a one-time intratumoral injection activated by radiotherapy, potentially scalable across various solid tumors, further advancing the company's R&D strategy.
- Strategic Collaboration: Nanobiotix's licensing agreement with Janssen Pharmaceutica for the global co-development and commercialization of JNJ-1900 underscores the company's robust collaborative network in oncology, aiming to enhance market penetration through various therapeutic combinations.
See More
Nanobiotix Unveils Preclinical Data for Nanoprimer Platform
- Preclinical Data Release: Nanobiotix presented preclinical data for its Nanoprimer platform at the American Association for Cancer Research annual meeting, showcasing its potential applications in lipid nanoparticle-delivered recombinant DNA, which could open new avenues in cancer treatment.
- Enhanced Bioavailability: Administering LNP-DNA intravenously in mouse models with Nanoprimer significantly reduced hepatic uptake and toxicity while increasing circulating levels of LNP-DNA, thereby improving drug bioavailability and patient treatment outcomes.
- Broad Application Potential: The positive preclinical results indicate that Nanoprimer has extensive applications in LNP-DNA formulations, RNA delivery, gene therapies, and advanced biologics, potentially transforming existing treatment modalities.
- Positive Market Reaction: NBTX shares closed up 4.10% at $33.79 last Friday, reflecting strong market expectations and increased investor confidence in the company's innovative technology.
See More
Nanobiotix's Nanoprimer Enhances LNP-DNA Delivery for Cancer Therapy
- Increased Bioavailability: Pre-treatment with Nanoprimer in mouse models significantly enhances the systemic bioavailability of LNP-DNA, indicating its potential to effectively overcome liver clearance issues associated with lipid nanoparticle therapies, thereby improving the efficacy of anti-tumor immunotherapy.
- Reduced Hepatic Toxicity: The study demonstrates that the application of Nanoprimer decreases liver uptake and toxicity of LNP-DNA, improving hepatic tolerability, which is crucial for enhancing patient safety during treatment.
- Mitigated Inflammatory Response: The pre-treatment with Nanoprimer attenuates the activation of the cGAS-STING pathway, reducing related inflammatory responses, which may contribute to improved overall treatment outcomes and minimized side effects.
- Broad Applicability: The potential applications of Nanoprimer extend beyond the current LNP-DNA designs, suggesting it could optimize other advanced drug delivery systems, thereby supporting future applications across multiple drug classes and advancing biotechnological innovations.
See More
Nanobiotix Reports Narrowed Net Loss and Cash Runway Guidance
- Improved Financial Performance: In 2025, Nanobiotix reported a narrowed net loss of €23.96 million, or €0.50 per share, down from €68.13 million and €1.44 per share the previous year, indicating progress in financial management despite ongoing losses.
- Significant Revenue Growth: The company achieved revenue and other income of €32.59 million in 2025, a substantial improvement from a negative €7.19 million in the prior year, which included a one-off positive revenue recognition of €21.8 million under IFRS15, reflecting increased market acceptance of its products.
- Strategic Financing Agreement: Nanobiotix entered into a non-dilutive royalty monetization agreement with HealthCare Royalty for up to $71 million, of which $50 million was received in December 2025, providing crucial funding support expected to extend operations into 2028.
- Clinical Data Outlook: Clinical data readouts for JNJ-1900 are anticipated in 2026, covering NSCLC, pancreatic cancer, melanoma, and esophageal cancer, and positive results could further enhance the company's market position in cancer treatment.
See More
Nanobiotix Reports FY 2025 Financial Results
- Financial Performance: Nanobiotix reported a FY 2025 GAAP EPS of -€0.50 with revenues of €29.6 million, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of December 31, 2025, Nanobiotix had €52.8 million in cash and cash equivalents, an increase from €49.7 million in 2024, reflecting improved cash management practices.
- Financial Guidance: The company anticipates that its current cash reserves will fund operations into early 2028, contingent upon receiving the remaining $21 million funding from HCRx expected one year post-closing, providing a buffer for ongoing operations.
- Milestone Funding: This cash flow forecast excludes any milestone receipts, indicating that the company will still rely on external financing for future cash inflows, which adds to its financial risk.
See More
Nanobiotix Receives FDA Approval for Study Protocol Amendment
- FDA Approval: Nanobiotix (NBTX) announced that the FDA has accepted a protocol amendment for the NANORAY-312 study evaluating JNJ-1900 in locally advanced head and neck squamous cell cancers, marking a significant advancement in the company's oncology research.
- Study Design Changes: The new protocol amendment submitted by Johnson & Johnson eliminates the interim analysis and modifies the final analysis to include fewer events, which is expected to expedite the research timeline and potentially shorten the path to market.
- Product Background: JNJ-1900 (NBTXR3) is an investigational oncology product made of functionalized hafnium oxide nanoparticles administered via a one-time intratumoral injection and activated by radiotherapy, demonstrating potential across multiple solid tumor indications.
- Stock Price Fluctuation: Despite NBTX's stock trading between $3.26 and $41.89 over the past year, it closed at $31.16 on Monday, down 11.28%, reflecting market caution regarding the study's progress.
See More
Nanobiotix Announces FDA Acceptance of Protocol Amendment for NANORAY-312 Clinical Trial
- Protocol Amendment: Nanobiotix announced the FDA's acceptance of a protocol amendment for its NANORAY-312 study, eliminating the planned interim analysis and modifying the final analysis to include fewer events, which could accelerate the global registration pathway for JNJ-1900 in head and neck cancer, thereby providing earlier revenue generation opportunities for the company.
- Revenue Potential: Under the licensing agreement, Nanobiotix anticipates receiving hundreds of millions in aggregate payments over the next few years, contingent upon achieving remaining development and regulatory milestones related to JNJ-1900 in head and neck and lung cancers, significantly enhancing the company's financial position and market competitiveness.
- Innovative Mechanism: JNJ-1900 (NBTXR3) is a novel oncology product designed to induce significant tumor cell death through a one-time intratumoral injection activated by radiotherapy, potentially scalable across various solid tumors, further advancing the company's R&D strategy.
- Strategic Collaboration: Nanobiotix's licensing agreement with Janssen Pharmaceutica for the global co-development and commercialization of JNJ-1900 underscores the company's robust collaborative network in oncology, aiming to enhance market penetration through various therapeutic combinations.
See More
Nanobiotix Unveils Preclinical Data for Nanoprimer Platform
- Preclinical Data Release: Nanobiotix presented preclinical data for its Nanoprimer platform at the American Association for Cancer Research annual meeting, showcasing its potential applications in lipid nanoparticle-delivered recombinant DNA, which could open new avenues in cancer treatment.
- Enhanced Bioavailability: Administering LNP-DNA intravenously in mouse models with Nanoprimer significantly reduced hepatic uptake and toxicity while increasing circulating levels of LNP-DNA, thereby improving drug bioavailability and patient treatment outcomes.
- Broad Application Potential: The positive preclinical results indicate that Nanoprimer has extensive applications in LNP-DNA formulations, RNA delivery, gene therapies, and advanced biologics, potentially transforming existing treatment modalities.
- Positive Market Reaction: NBTX shares closed up 4.10% at $33.79 last Friday, reflecting strong market expectations and increased investor confidence in the company's innovative technology.
See More
Nanobiotix's Nanoprimer Enhances LNP-DNA Delivery for Cancer Therapy
- Increased Bioavailability: Pre-treatment with Nanoprimer in mouse models significantly enhances the systemic bioavailability of LNP-DNA, indicating its potential to effectively overcome liver clearance issues associated with lipid nanoparticle therapies, thereby improving the efficacy of anti-tumor immunotherapy.
- Reduced Hepatic Toxicity: The study demonstrates that the application of Nanoprimer decreases liver uptake and toxicity of LNP-DNA, improving hepatic tolerability, which is crucial for enhancing patient safety during treatment.
- Mitigated Inflammatory Response: The pre-treatment with Nanoprimer attenuates the activation of the cGAS-STING pathway, reducing related inflammatory responses, which may contribute to improved overall treatment outcomes and minimized side effects.
- Broad Applicability: The potential applications of Nanoprimer extend beyond the current LNP-DNA designs, suggesting it could optimize other advanced drug delivery systems, thereby supporting future applications across multiple drug classes and advancing biotechnological innovations.
See More
Nanobiotix Reports Narrowed Net Loss and Cash Runway Guidance
- Improved Financial Performance: In 2025, Nanobiotix reported a narrowed net loss of €23.96 million, or €0.50 per share, down from €68.13 million and €1.44 per share the previous year, indicating progress in financial management despite ongoing losses.
- Significant Revenue Growth: The company achieved revenue and other income of €32.59 million in 2025, a substantial improvement from a negative €7.19 million in the prior year, which included a one-off positive revenue recognition of €21.8 million under IFRS15, reflecting increased market acceptance of its products.
- Strategic Financing Agreement: Nanobiotix entered into a non-dilutive royalty monetization agreement with HealthCare Royalty for up to $71 million, of which $50 million was received in December 2025, providing crucial funding support expected to extend operations into 2028.
- Clinical Data Outlook: Clinical data readouts for JNJ-1900 are anticipated in 2026, covering NSCLC, pancreatic cancer, melanoma, and esophageal cancer, and positive results could further enhance the company's market position in cancer treatment.
See More
Nanobiotix Reports FY 2025 Financial Results
- Financial Performance: Nanobiotix reported a FY 2025 GAAP EPS of -€0.50 with revenues of €29.6 million, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of December 31, 2025, Nanobiotix had €52.8 million in cash and cash equivalents, an increase from €49.7 million in 2024, reflecting improved cash management practices.
- Financial Guidance: The company anticipates that its current cash reserves will fund operations into early 2028, contingent upon receiving the remaining $21 million funding from HCRx expected one year post-closing, providing a buffer for ongoing operations.
- Milestone Funding: This cash flow forecast excludes any milestone receipts, indicating that the company will still rely on external financing for future cash inflows, which adds to its financial risk.
See More
